A recent systematic review and meta-analysis, which included seven RCTs and a total of 6609 adults with T2D irrespective of their background glucose-lowering treatment, demonstrated a dose-dependent superiority of tirzepatide in reducing body weight compared to long-acting GLP-1 RAs, insulin or a placebo. Here, GLP1R is linked to type 2 diabetes mellitus.